Qui Tam and Whistleblower Litigation for Federal Contractors at Fort Detrick and Frederick, Maryland
By Anthony I. Shin, Esq., Shin Law Office
BOTTOM LINE UP FRONT
If you work at a Fort Detrick biomedical or biological defense contractor, at USAMRIID, USAMRDC, USAMRICD, the NCI Frederick National Laboratory for Cancer Research, the NIAID Integrated Research Facility, or one of the contractors that supports the Frederick biomedical research mission and have seen something at your employer that looks like fraud against the government, the decision about what to do next is one of the most consequential of your career. The False Claims Act lets you sue on behalf of the United States as a qui tam relator and share in any recovery. Both 31 U.S.C. §3730(h) and (for civilian agency contractor work) 41 U.S.C. §4712 protect you from retaliation. Filing is irreversible once the seal goes on. Take a breath and read this before you do anything else.
I am Anthony Shin and I represent federal contractor employees who file in the District of Maryland. Call 571-445-6565 or use my contact page to Schedule a Consultation. The first call is protected by attorney-client privilege.
Why Fort Detrick FCA Cases Have Their Own Profile
Fort Detrick is the country’s premier biomedical and biological defense research installation. The US Army Medical Research Institute of Infectious Diseases (USAMRIID) operates from the installation as the Department of Defense’s lead laboratory for medical countermeasure research on biological threats. The US Army Medical Research and Development Command (USAMRDC) is headquartered at Fort Detrick. The US Army Medical Research Institute of Chemical Defense (USAMRICD), though located primarily at Aberdeen, coordinates with the Detrick portfolio on chemical defense work. The NCI Frederick National Laboratory for Cancer Research (operated for the National Cancer Institute under a Federally Funded Research and Development Center model) runs cancer and HIV/AIDS research from the same campus. The NIAID Integrated Research Facility provides BSL-3 and BSL-4 biocontainment for infectious disease research. The US Army Medical Materiel Agency (USAMMA) manages medical materiel for the Army from Fort Detrick.
The contractor footprint reflects the biomedical and biological defense mission. Leidos Biomedical Research operates the Frederick National Laboratory under prime contract to NCI. Battelle operates a number of biocontainment facilities and supports biological defense research. Charles River Laboratories and BioReliance handle preclinical and toxicology work. KBR, SAIC, Booz Allen Hamilton, ManTech, GDIT, and a long list of biotech and vaccine development contractors round out the workforce. Off-base contractor offices fill the city of Frederick, Ballenger Creek, and Walkersville. The Fort Detrick FCA picture is weighted toward biomedical research grant compliance, biocontainment facility compliance, IRB and IACUC compliance, vaccine and biologic acceptance testing, and the cleared services patterns that wrap around the broader cleared workforce.
Local Federal Court Picture
Fort Detrick federal contractor qui tam cases are filed in the United States District Court for the District of Maryland. Cases tied to Frederick County typically run through the Greenbelt Division at 6500 Cherrywood Lane in Greenbelt. The District of Maryland does not have EDVA’s rocket docket, but cases still move on a defined schedule, and the Fourth Circuit precedent that governs FCA materiality, scienter, and qui tam procedure applies equally in both districts.
The Civil Division of the United States Attorney’s Office for the District of Maryland handles the DOJ investigation during the seal period. HHS Office of Inspector General (for NCI Frederick and NIAID work), Army Criminal Investigation Division (for USAMRIID, USAMRDC, and USAMRICD matters), DCIS, DCAA, USDA Office of Inspector General (for select agent oversight), CDC oversight (for select agent and BSL-3/BSL-4 compliance), DOD IG, and the FBI’s Baltimore field office participate as the underlying conduct touches their lanes. Biocontainment facility compliance cases often draw broad inter-agency interest given the public health and biosecurity stakes.
Common Fort Detrick Fraud Patterns
The patterns I see most often from the Fort Detrick workforce sit in four overlapping categories. First, biomedical research grant compliance fraud: USAMRMC, NCI Frederick, and NIAID grant and contract work where effort reporting, cost-sharing certifications, scope-of-work compliance, or research results were knowingly false. Second, biocontainment facility compliance fraud: BSL-3 and BSL-4 protocol compliance, select agent regulations under the Federal Select Agent Program, personnel reliability program certifications, and facility certification documentation that diverged from actual practice. Third, IRB and IACUC compliance fraud: Institutional Review Board (human subjects research) and Institutional Animal Care and Use Committee (animal research) compliance certifications that were knowingly false, including misrepresentations about protocol modifications, adverse event reporting, or enrollment criteria. Fourth, vaccine and biologic acceptance testing fraud: lot acceptance certifications, qualification certifications, and quality assurance certifications on vaccines, antibodies, antitoxins, and other biological products that diverged from actual test results.
Biocontainment compliance fraud deserves its own mention because the stakes go beyond financial harm. The Federal Select Agent Program governs the handling of biological agents and toxins that pose a severe threat to public, animal, or plant health. CDC and USDA jointly administer the program. When workers know that select agent inventory records, personnel reliability program certifications, BSL-3 or BSL-4 protocol compliance, or facility certifications are knowingly false, the harm risk is to public health and biosecurity, not just to the federal fisc. The Escobar materiality analysis is typically straightforward because the government would not knowingly accept performance falling short of biocontainment requirements. IRB and IACUC compliance fraud similarly carries harm risk to research subjects (human and animal). False cybersecurity certifications became the most active enforcement area generally after the October 2021 launch of the DOJ Civil Cyber-Fraud Initiative, and biomedical research contractors handling Protected Health Information and Controlled Unclassified Information sit within that framework.
How I Help
When a Fort Detrick federal contractor employee calls me about a potential qui tam case, my first conversation works through five things. The strength of the evidence. The materiality analysis under Escobar. The scienter analysis under SuperValu. The first-to-file risk under Section 3730(b)(5). And your professional and financial circumstances. The conversation usually takes one to two hours and is protected by attorney-client privilege. I do not commit to representation in the first meeting; I want to understand the case before either of us makes a commitment.
If the recommendation is qui tam filing, I prepare the complaint, the DOJ written disclosure statement, and the supporting documentation, file under seal in the District of Maryland, and coordinate with the DOJ during the investigation phase. Biomedical research cases require careful handling of Protected Health Information (PHI) and human subjects research data. Biocontainment cases require careful attention to select agent regulations, security-sensitive information, and (where applicable) classified material. Animal research cases implicate IACUC records that are themselves part of the regulatory framework. We work the case using lawful means that respect those handling requirements. If the recommendation is a Section 3730(h) or 41 U.S.C. §4712 retaliation claim alone, I prepare and file that. If the recommendation involves immediate biosecurity or public health harm risk, additional internal escalation pathways may be appropriate alongside the qui tam analysis.
Frequently Asked Questions
What if my work involves USAMRIID biocontainment or BSL-3/BSL-4 research?
Great question, and the honest answer is that biocontainment and BSL-3/BSL-4 research generates some of the highest-stakes FCA cases because the harm risk goes beyond financial. False select agent inventory records, false personnel reliability program certifications, false BSL-3 or BSL-4 protocol compliance certifications, or false facility certifications create both FCA exposure and serious public health concerns. The Escobar materiality analysis is typically straightforward because the government would not knowingly accept performance falling short of biocontainment requirements. Workers with direct knowledge of these gaps are in a strong relator position, and CDC, USDA, and HHS OIG typically engage early in the investigation.
Are research grant or IRB compliance cases actionable?
Honest answer, yes, and these are among the most common civilian agency FCA case categories in the biomedical research world. Research grants run on effort reporting, cost-sharing, and scope-of-work certifications. IRB approvals run on protocol-specific compliance certifications: protocol modifications, adverse event reporting, enrollment criteria, informed consent procedures. When workers know that any of these certifications are knowingly false and material to the government’s payment decision, FCA liability follows. HHS OIG typically participates in the DOJ investigation. The first consultation walks through the specifics of your knowledge.
How much can I recover as a Fort Detrick qui tam relator?
Fair question because the math matters. If the government intervenes and the case succeeds, you receive 15 to 25 percent of the recovery, plus attorney fees and costs. If the government declines and you proceed alone, 25 to 30 percent. Biomedical research and biocontainment contractor qui tam recoveries have ranged from low six figures to nine figures, depending on the size of the underlying fraud and the volume of grant or contract invoices involved. Large biomedical research grant fraud cases and multi-year biocontainment compliance cases tend to fall toward the higher end.
What if another worker already filed a qui tam on the same fraud?
Section 3730(b)(5) bars qui tam complaints based on the same essential facts already alleged in another pending case. Only the first relator to file can proceed. The seal makes prior filings invisible to you before you file. Counsel can run searches and analyses to assess this risk, though the seal limits certainty. The Fort Detrick workforce is large but program-tight, especially within USAMRIID, NCI Frederick, and the NIAID Integrated Research Facility teams, so overlap with other potential relators is a real concern when the underlying fraud touches a broad pattern of conduct.
Schedule a Consultation
I represent biomedical and biological defense federal contractor employees at Fort Detrick, USAMRIID, USAMRDC, USAMRICD, NCI Frederick, the NIAID Integrated Research Facility, and across the Frederick County biomedical contractor corridor who have seen fraud at their employer and are deciding what to do about it. Qui tam relator representation in the District of Maryland. Section 3730(h) and 41 U.S.C. §4712 retaliation defense. NDAA, SOX, and Dodd-Frank whistleblower claims. Biocontainment and select agent compliance issues. IRB and IACUC compliance issues. Internal reporting strategy. Classified-program and CUI handling. The first conversation is protected by attorney-client privilege and usually takes one to two hours.
Call 571-445-6565 or visit my contact page to Schedule a Consultation.
Related Guides
The sub-hub for this series:
The cornerstone hub for the full series:
Federal Contracting Law in Virginia and Maryland: A Northern Virginia Attorney’s Complete Guide
Companion clearance guide for the same workforce:
Security Clearance Defense for Federal Contractors at Fort Detrick and Frederick, Maryland
References
10 U.S.C. §2409 (NDAA Whistleblower Protections for Defense Contractor Employees).
31 U.S.C. §3729 (False Claims Act Liability).
31 U.S.C. §3730 (False Claims Act Procedures, Qui Tam, Anti-Retaliation).
41 U.S.C. §4712 (NDAA Whistleblower Protections for Civilian Agency Contractor Employees).
42 U.S.C. §262a; 7 U.S.C. §8401 (Federal Select Agent Program statutory framework).
7 C.F.R. Part 331; 9 C.F.R. Part 121; 42 C.F.R. Part 73 (Federal Select Agent Program regulations).
45 C.F.R. Part 46 (Common Rule, Protection of Human Subjects).
9 C.F.R. Parts 1-4 (Animal Welfare Act regulations).
Cochise Consultancy, Inc. v. United States ex rel. Hunt, 587 U.S. 262 (2019).
Department of Justice Civil Cyber-Fraud Initiative (October 2021).
Eberhardt v. Integrated Design and Construction, Inc., 167 F.3d 861 (4th Cir. 1999).
FAR Part 31 (Contract Cost Principles and Procedures), 48 C.F.R. Part 31.
NIH Grants Policy Statement.
NIST Special Publication 800-171, Protecting Controlled Unclassified Information in Nonfederal Systems and Organizations.
United States ex rel. Schutte v. SuperValu Inc., 598 U.S. 739 (2023).
Universal Health Services, Inc. v. United States ex rel. Escobar, 579 U.S. 176 (2016).
U.S. District Court for the District of Maryland. https://www.mdd.uscourts.gov
